The combination of Sofosbuvir and Daclatasvir provided pangenotyic treatment of HVC by inhibiting NS5B and NS5A.
Simeprevir inhibits the NS3A/4 components: https://en.wikipedia.org/wiki/Simeprevir
If you’ve been wondering if inhibiting NS3A/4 + NS5A + NS5B might work really well consider the IMPACT study that was reported at the AASLD November 2015 meeting – 100% might well be here:
AASLD_IMPACTStudy.pdf
Before you get too excited there is no generic Simeprevir currently available and the cheapest price you might find it is for $7500 USD for 3×28 in Egypt, but it does look very promising.
Note that Simeprevir is not active against GT3 and you don’t want the Q80K mutation
http://www.ncbi.nlm.nih.gov/pubmed/22326470
http://www.ncbi.nlm.nih.gov/pubmed/19852962
http://www.ncbi.nlm.nih.gov/pubmed/26392483
.
